NDA 019655 · Viiv Hlthcare
Retrovir
Zidovudine · Oral · Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Mar 19, 1987
Approved uses
6
Original approval plus efficacy supplements
Registered trials
497
105 Phase 3, 3 recruiting
FAERS reports
13,354
12,637 serious, 1,659 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF HEMATOLOGICAL TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS RETROVIR (zidovudine) capsules, oral solution, and injection have been associated with hematologic toxicity including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease [see Warnings and Precautions ( 5.1 )] . Prolonged use of RETROVIR has been associated with symptomatic myopathy [see Warnings and Precautions ( 5. 2)] . Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including RETROVIR and other antiretrovirals. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur [see Warnings and Precautions ( 5. 3)] . WARNING: RISK OF HEMATOLOGICAL TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND...
What it is approved for
From the label in effect Nov 13, 2024.
RETROVIR is a nucleoside analogue reverse transcriptase inhibitor indicated for: • Treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. ( 1.1 ) • Prevention of maternal-fetal HIV-1 transmission. ( 1.2 ) 1.1 Treatment of HIV-1 RETROVIR, a nucleoside reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 1.2 Prevention of Maternal-Fetal HIV-1 Transmission RETROVIR is indicated for the prevention of maternal-fetal HIV-1 transmission [see Dosage and Administration ( 2.3 )]. The indication is based on a dosing regimen that included 3 components: 1. antepartum therapy of HIV‑1–infected mothers 2. intrapartum therapy of HIV‑1–infected mothers 3. post-partum therapy of HIV‑1–exposed neonate Points to consider prior to initiating RETROVIR in pregnant women for the prevention of maternal-fetal HIV-1 transmission include: • In most cases, RETROVIR for prevention of maternal-fetal HIV-1 transmission should be given in combination with other antiretroviral drugs. • Prevention of HIV-1 transmission in women who have received RETROVIR for a prolonged period before pregnancy has not been evaluated. • Because the fetus is most susceptible to the potential teratogenic effects of drugs during the first 10 weeks of gestation and the risks of therapy with RETROVIR during that period are not fully known, women in the first trimester of pregnancy who do not require immediate initiation of antiretroviral therapy for their own health may consider delaying use; this indication is based on use after 14 weeks’ gestation.
Mechanism: Zidovudine is an antiretroviral agent [see Microbiology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 19, 2008 Supplement 46 · Efficacy LabelLetter
- Oct 4, 1996 Supplement 26 · Efficacy
- Oct 4, 1996 Supplement 29 · Efficacy
- Aug 8, 1994 Supplement 23 · Efficacy · priority review
- Jan 12, 1990 Supplement 13 · Efficacy
- Mar 19, 1987 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- RETROVIR · ZIDOVUDINE 100MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Zidovudine" as an intervention, any sponsor and status, largest first.
- A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected PatientsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00002382 · 4,000 participants
Drug: Saquinavir · For: HIV Infections
Sites: Nutley, New Jersey
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited CountriesPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01061151 · 3,747 participants · Start Mar 1, 2011 · Primary completion Sep 30, 2016
Drug: Zidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers and 6 more · For: HIV Infections
Sites: Pune, India; Blantyre, Malawi; Lilongwe, Malawi · 14 sites in all
- Preventing Sexual Transmission of HIV With Anti-HIV DrugsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00074581 · 3,526 participants · Start Feb 2005 · Primary completion May 2015
Drug: Atazanavir; Didanosine and 8 more · For: HIV Infections
Sites: Boston, Massachusetts; Gaborone, Botswana; Nova Iguaçu, Brazil · 17 sites in all
- Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV TransmissionPivotal-lookingCompleted
Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
NCT00115648 · 3,300 participants (planned) · Start Apr 2004 · Primary completion Aug 2007
Drug: Nevirapine; AZT and 3 more · For: HIV Infections
Sites: Blantyre, Malawi
- Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected IndividualsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000736 · 3,200 participants
Drug: Zidovudine · For: HIV Infections
Sites: Los Angeles, California; Oakland, California; Palo Alto, California · 43 sites in all
- A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous TreatmentPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00002334 · 3,000 participants
Drug: Saquinavir; Zidovudine and 1 more · For: HIV Infections
Sites: Phoenix, Arizona; Sacramento, California; San Francisco, California · 26 sites in all
- Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive WomenPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02181933 · 2,648 participants · Start Apr 1999 · Primary completion Jan 2001
Drug: Nevirapine; Zidovudine (ZDV) and 1 more · For: HIV Infections
- Breastfeeding, Antiretroviral, and Nutrition StudyPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT00164736 · 2,369 participants · Start Mar 2004 · Primary completion Jan 2010
Drug: Maternal zidovudine/lamivudine/lopinavir-ritonavir; Infant nevirapine · For: HIV Infections
Sites: Lilongwe, Malawi
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- foetal exposure during pregnancy2,183
- drug exposure during pregnancy1,074
- anaemia937
- virologic failure816
- drug resistance732
- premature baby731
- exposure during pregnancy663
- pathogen resistance599
- viral mutation identified568
- maternal exposure during pregnancy523
- pyrexia471
- lipodystrophy acquired436
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 544 |
| 2005 | 542 |
| 2006 | 791 |
| 2007 | 608 |
| 2008 | 579 |
| 2009 | 630 |
| 2010 | 597 |
| 2011 | 465 |
| 2012 | 423 |
| 2013 | 408 |
| 2014 | 457 |
| 2015 | 697 |
| 2016 | 1,264 |
| 2017 | 987 |
| 2018 | 834 |
| 2019 | 722 |
| 2020 | 908 |
| 2021 | 541 |
| 2022 | 460 |
| 2023 | 398 |
| 2024 | 193 |
| 2025 | 148 |
| 2026 | 143 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Half-dose zidovudine.
de Truchis P, Salmon D, Matheron S, et al. · Lancet 1991 · Clinical Trial, Comparative Study
- Zidovudine (AZT).
· Lancet 1987 · Clinical Trial, Editorial
- Concentration-controlled zidovudine therapy.
Fletcher CV, Acosta EP, Henry K, et al. · Clin Pharmacol Ther 1998 · Clinical Trial, Randomized Controlled Trial
- Zidovudine (Retrovir) update.
Rachlis AR · CMAJ 1990 · Clinical Trial, Guideline
- Retrovir trial.
Lehrman SN · Ann Emerg Med 1989 · Clinical Trial, Letter
- Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
Veroniki AA, Antony J, Straus SE, et al. · PLoS One 2018 · Comparative Study, Network Meta-Analysis
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.